In addition, the literature is inconclusive on in vivo levels of these metabolites in AD because increased, decreased, and unaltered levels of PME and PDE have been observed in comparison with cognitively normal controls [37–42]. This evidence concerns the gene ALDH7A1 and Alzheimer disease.